Physician profile
Diane Conrad
NPI 1578504262
$1,165.22
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $943 · 2020: $201 · 2023: $21.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $21.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $21.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $255.58 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $223.60 | 2019-2020 | |
| Pfizer INC. | $201.83 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $129.84 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.84 | 2019 | |
| Glaxosmithkline, LLC. | $62.75 | 2019-2020 | |
| Amgen INC. | $39.83 | 2019 | |
| Novartis Pharmaceuticals Corporation | $34.21 | 2019 | |
| Merck Sharp & Dohme LLC | $22.75 | 2019 | |
| Ferring Pharmaceuticals INC. | $17.61 | 2019 | |
| Coherus Oncology, INC. | $17.46 | 2020 | |
| Sanofi-Aventis U.S. LLC | $16.06 | 2019 | |
| Mylan Specialty L.P. | $15.05 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $14.60 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diane Conrad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.